Safety and Efficacy of Oral Acetyl-l-Carnitine (ALC) in Non-Anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue.

Trial Profile

Safety and Efficacy of Oral Acetyl-l-Carnitine (ALC) in Non-Anemic Potentially Curable Breast Cancer Subjects Undergoing Adjuvant Radiation Therapy Who Have Moderate to Severe Fatigue.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Levacecarnine (Primary)
  • Indications Fatigue
  • Focus Therapeutic Use
  • Sponsors Leadiant Biosciences
  • Most Recent Events

    • 28 Feb 2017 According to a Leadiant Biosciences media release, this trial was originally conducted by Sigma-Tau Pharmaceuticals, Inc. but later on this company's name changed to Leadiant Biosciences
    • 05 Jun 2009 Official Title amended as reported by ClinicalTrials.gov.
    • 05 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top